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MICAbstract It is our ongoing effort to search new bio-active molecules and as a part of this, several
chemical processes like condensation, cycloaddition were carried out to furnish 2-((1-(4-(4-(arylid-
ene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)phenyl)ethylidene)hydrazono)thiazolidin-4-ones
(4a–o). All compounds were characterized by IR, 1H NMR, 13C NMR and mass spectra. Newly
synthesized compounds were screened for their antibacterial and antifungal activities on Escherichia
coli, Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus pyogenes, Candida albicans,
Aspergillus niger and Aspergillus clavatus by bioassay namely serial broth dilution. On the basis
of statistical analysis, it was observed that these compounds showed signiﬁcant co-relation. The
synthesized compounds showed potent antimicrobial activity against test microorganisms.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Recently, antibiotic-resistant microbes are making their inexo-
rable march and medicinal chemists have now realized that the
discovery of more powerful antibiotics is not the only answer
to this threat. But, a real need exists in searching a novel anti-
microbial that expresses antimicrobial properties, possibly act-
ing through mechanisms different from those of existing drugs.In this context, it is very essential to successfully develop novel,
efﬁcient bio-active molecules with clinically unexploited mode
of action (Rubinstein, 1994; Brumﬁtt and Hamilton-Miller,
1994; Neu, 1992; Barry et al., 2000).
The pharmacological interest of the imidazole ring has been
established, nitroimidazoles being extensively used in therapy
against amoebic, trichomonal, giardial and anaerobic infec-
tions or as hypoxic cell radiosensitizers (Nair and Nagarajan,
1983). Metronidazole and substituted imidazoles are well-
tolerated drugs that are potentially active against leishmania,
but their use in the treatment of cutaneous and visceral leish-
maniasis has produced conﬂicting results (Gangneux et al.,
1999). Clotrimazole is an antifungal medication commonly
used in the treatment of fungal infections such as vaginal yeast
infections, oral thrush and ringworm. The imidazole moiety
which incorporates both p-excessive and p-deﬁcient character-
S590 N.C. Desai et al.istics has proven to be a master key in the range of drug
target families (Abdel-Meguid et al., 1994; Muller, 2003).
Compounds incorporating the imidazole scaffold are known
as inhibitors of p38 MAPK (Laufer et al., 2004), JNK (Lis-
nock et al., 2002), B-Raf kinase (Takle et al., 2006), transform-
ing growth factor b-1 (TGF-b1) type 1 receptor kinase (Laping
et al., 2002) and acyl-CoA: cholesterol O-acyl transferase
(ACAT) (Riddell et al., 1996). Imidazoles substituted with 2-
arylamino functionality have been reported to have potent
and selective agonist activity at a2-adrenoceptors (Munk
et al., 1997). Further the chemistry of thiazolidinone ring sys-
tem is of considerable interest as it is a core structure in various
synthetic pharmaceuticals displaying a broad spectrum of bio-
logical activities (Desai et al., 2012a). The thiazolidinone nu-
cleus also appears frequently in the structure of various
natural products, notably thiamine, compounds possessing
cardiac and glycemic beneﬁts such as troglitazone (Ghazzi
et al., 1997) and many metabolic products of fungi and prim-
itive marine animals, including 2-(aminoalkyl)-thiazole-4-
carboxylic acids (Ulrich et al., 1987). Numerous thiazolidinone
derivatives have shown signiﬁcant bioactivities such as anti-
diarrhoeal (Diurno et al., 1997), anticonvulsant (Ragab
et al., 1997), antimicrobial (Sattigeri et al., 2005), antidiabetic
(Norisada et al., 2004), antihistaminic (Previtera et al., 1994),
anticancer (Havrylyuk et al., 2009), anti HIV (Rawal et al.,
2005), Ca2+ channel blocker (Kato et al., 1999b), PAF antag-
onist (Tanabe et al., 1991), cardioprotective (Kato et al.,
1999a), antiischemic (Adachi et al., 1999), COX inhibitory
(Ottana et al., 2002), anti-platelet activating factor (Tanabe
et al., 1995), non-peptide thrombin receptor antagonist (Kato
et al., 1999), tumor necrosis factor-a antagonist (Voss et al.,
2003) and nematicidal activities. Certain commercially avail-
able drugs containing imidazole and 4-thiazolidinone nucleus
are shown in Fig. 1.
It must be emphasized, that a combination of imidazole
template with 4-thiazolidinone is a well-known approach for
a drug-like molecule’s build-up, which allows achieving new
pharmacological proﬁle, action strengthening or toxicity low-
ering. As part of our ongoing research in developing of new
bio-active molecules (Desai et al., 2011, 2012b,c,d,e,f), we tried
to study the inﬂuence of imidazole and 4-thiazolidinone scaf-
fold combination on the antimicrobial effect. The structural
variations were explored by substituting the imidazoline moi-
ety in position four and by introduction of different arylideneFigure 1 Commercially available drugs containsubstituents. The latter were recently exploited as bioactive
arms on heterocyclic scaffolds useful to pharmacological effect
realization of 4-thiazolidinone based compounds.
2. Experimental
2.1. General
All reactions except those in aqueous media were carried out
by standard techniques for the exclusion of moisture. Melting
points were determined on an electro thermal melting point
apparatus and were reported uncorrected. TLC on silica gel
plates (Merck, 60, F254) was used for purity checking and reac-
tion monitoring. Column chromatography on silica gel
(Merck, 70–230 mesh and 230–400 mesh ASTH for ﬂash chro-
matography) was applied when necessary to isolate and purify
the reaction products. Elemental analysis (% C, H, N) was car-
ried out by a Perkin-Elmer 2400 CHN analyzer. IR spectra of
all compounds were recorded on a Perkin-Elmer FT-IR spec-
trophotometer in KBr. 1H NMR spectra were recorded on
Varian Gemini 300 MHz and 13C NMR spectra on Varian
Mercury-400, 100 MHz in DMSO-d6 as a solvent and tetra-
methylsilane (TMS) as an internal standard. Mass spectra were
scanned on a Shimadzu LCMS 2010 spectrometer. Anhydrous
reactions were carried out in oven-dried glassware in a nitro-
gen atmosphere.
2.2. General procedure for preparation 1-(4-acetylphenyl)-4-
(arylidene)-2-phenyl-1H-imidazol-5(4H)-ones (2a-o)
Compounds 1-(4-acetylphenyl)-4-(arylidene)-2-phenyl-1H-imi-
dazol-5(4H)-ones (2a–o) were prepared according to the litera-
ture method (Badr and Mahgoub, 1989).
2.3. General procedure for preparation 2-(1-(4-(4-(arylidene)-
5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)phenyl)-
ethylidene)hydrazinecarbothioamides (3a-o)
A mixture of compounds 1-(4-acetylphenyl)-4-(arylidene)-2-
phenyl-1H-imidazol-5(4H)-ones (2a–o) (0.01 mol) and thio-
semicarbazide (0.01 mol) in ethanol (40 mL) was heated under
reﬂux for 1 h. The separated solid was recrystallized by ethanol
to give compounds (3a–o).ing imidazoline and thiazolidinone nucleus.
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imidazol-1-yl)phenyl)ethylidene)hydrazine carbothioamide (3a)
Yield: 67%; m.p.: 182–184 C; IR (KBr) mmax/cm1: 3442, 3370
(NH2), 3237 (NH), 3064 (C–H, aromatic), 2921, 3002 (C–H),
1684 (C‚O), 1579 (C‚N), 1513 (C‚C), 1330 (C‚S); 1H
NMR (300 MHz, DMSO-d6, d, ppm): 2.30 (s, 3H, CH3),
6.43 (brs, 2H, D2O exch., NH2), 6.97 (t, J= 8.4 Hz, 1H,
Ar–H), 7.12 (t, J= 8.4 Hz, 2H, Ar–H), 7.30 (d, J= 7.4 Hz,
2H, Ar–H), 7.39 (s, 1H, CH‚C), 7.48 (d, J= 7.2 Hz, 2H,
Ar–H), 7.54 (t, J= 8.1 Hz, 2H, Ar–H), 7.59 (t, J= 8.0 Hz,
1H, Ar–H), 7.94 (d, J= 8.0 Hz, 2H, Ar–H), 8.02 (d,
J= 7.6 Hz, 2H, Ar–H), 8.70 (s, 1H, D2O exch., NH);
13C
NMR (100 MHz, DMSO-d6, d, ppm): 18.3, 114.6, 124.3,
127.4, 128.2, 128.3, 128.7, 128.8, 129.4, 130.1, 131.4, 132.8,
135.2, 136.4, 141.3, 147.3, 158.3, 170.6, 179.4; LCMS (m/z):
439 (M+); Anal. Calcd. For C25H21N5OS: C-68.32, H-4.82,




Yield: 63%; m.p.: 193–195 C; IR (KBr) mmax/cm1: 3432, 3363
(NH2), 3238 (NH), 3054 (C–H, aromatic), 2928, 3012 (C–H),
1681 (C‚O), 1572 (C‚N), 1522 (C‚C), 1335 (C‚S), 720
(C–Cl stretching); 1H NMR (300 MHz, DMSO-d6, d, ppm):
2.34 (s, 3H, CH3), 6.44 (brs, 2H, D2O exch., NH2), 7.17 (t,
J= 8.0 Hz, 1H, Ar–H), 7.21 (t, J= 7.4 Hz, 1H, Ar–H), 7.34
(d, J= 8.4 Hz, 1H, Ar–H), 7.42 (d, J= 8.4 Hz, 1H, Ar–H),
7.49 (d, J= 7.2 Hz, 2H, Ar–H), 7.56 (t, J= 8.0 Hz, 2H, Ar–
H), 7.61 (t, J= 8.6 Hz, 1H, Ar–H), 7.70 (s, 1H, CH‚C),
7.97 (d, J= 7.6 Hz, 2H, Ar–H), 8.05 (d, J= 7.4 Hz, 2H,
Ar–H), 8.74 (s, 1H, D2O exch., NH);
13C NMR (100 MHz,
DMSO-d6, d, ppm): 18.3, 110.8, 124.3, 127.8, 128.2, 128.7,
128.8, 129.1, 129.4, 129.9, 130.1, 131.4, 132.5, 132.8, 134.5,
135.2, 141.3, 147.3, 158.3, 170.6, 179.4; LCMS (m/z): 473
(M+); Anal. Calcd. For C25H20ClN5OS: C-63.35, H-4.25, N-




Yield: 66%; m.p.: 187–189 C; IR (KBr) mmax/cm1: 3422, 3355
(NH2), 3252 (NH), 3062 (C–H, aromatic), 2924, 3003 (C–H),
1687 (C‚O), 1580 (C‚N), 1527 (C‚C), 1331 (C‚S), 735
(C–Cl stretching); 1H NMR (300 MHz, DMSO-d6, d, ppm):
2.37 (s, 3H, CH3), 6.47 (brs, 2H, D2O exch., NH2), 7.36 (s,
1H, CH‚C), 7.40 (d, J= 8.0 Hz, 2H, Ar–H), 7.46 (d,
J= 7.4 Hz, 2H, Ar–H), 7.54 (t, J= 8.2 Hz, 2H, Ar–H), 7.63
(t, J= 8.0 Hz, 1H, Ar–H), 7.68 (t, J= 8.4 Hz, 2H, Ar–H),
7.94 (d, J= 8.2 Hz, 2H, Ar–H), 8.01 (d, J= 7.4 Hz, 2H,
Ar–H), 8.78 (s, 1H, D2O exch., NH);
13C NMR (100 MHz,
DMSO-d6, d, ppm): 18.1, 114.4, 124.5, 128.2, 128.5, 128.7,
129.0, 129.5, 130.6, 131.3, 133.1, 133.3, 134.7, 135.8, 141.8,
147.3, 158.5, 170.7, 179.2; LCMS (m/z): 473 (M+); Anal.





Yield: 62%; m.p.: 176–178 C; IR (KBr) mmax/cm1: 3417, 3366
(NH2), 3243 (NH), 3052 (C–H, aromatic), 2917, 3006 (C–H),1691 (C‚O), 1574 (C‚N), 1533 (C‚C), 1328 (C‚S), 1151
(C–F stretching); 1H NMR (300 MHz, DMSO-d6, d, ppm):
2.34 (s, 3H, CH3), 6.44 (brs, 2H, D2O exch., NH2), 7.15 (t,
J= 8.4 Hz, 1H, Ar–H), 7.22 (d, J= 7.8 Hz, 1H, Ar–H),
7.39 (d, J= 8.2 Hz, 1H, Ar–H), 7.45 (d, J= 7.4 Hz, 2H,
Ar–H), 7.58 (t, J= 8.6 Hz, 2H, Ar–H), 7.64 (t, J= 9.0 Hz,
1H, Ar–H), 7.69 (d, J= 8.4 Hz, 1H, Ar–H), 7.92 (d,
J= 8.0 Hz, 2H, Ar–H), 8.08 (d, J= 7.2 Hz, 2H, Ar–H),
7.69 (s, 1H, CH‚C), 8.79 (s, 1H, D2O exch., NH);
13C
NMR (100 MHz, DMSO-d6, d, ppm): 18.6, 110.6, 115.3,
123.1, 124.5, 124.8, 128.2, 128.6, 128.8, 129.2, 129.6, 130.5,
131.7, 132.3, 135.6, 141.3, 147.5, 158.3, 161.3, 170.2, 179.1;
LCMS (m/z): 457 (M+); Anal. Calcd. For C25H20FN5OS: C-




Yield: 66%; m.p.: 195–197 C; IR (KBr) mmax/cm1: 3412,
3354 (NH2), 3251 (NH), 3077 (C–H, aromatic), 2922, 3004
(C–H), 1682 (C‚O), 1570 (C‚N), 1526 (C‚C), 1333
(C‚S), 1145 (C–F stretching); 1H NMR (300 MHz, DMSO-
d6, d, ppm): 2.33 (s, 3H, CH3), 6.48 (brs, 2H, D2O exch.,
NH2), 7.20 (d, J= 7.4 Hz, 2H, Ar–H), 7.39 (s, 1H, CH‚C),
7.43 (d, J= 8.2 Hz, 2H, Ar–H), 7.58 (t, J= 8.6 Hz, 2H, Ar–
H), 7.67 (t, J= 8.0 Hz, 1H, Ar–H), 7.75 (d, J= 7.4 Hz, 2H,
Ar–H), 7.93 (d, J= 8.0 Hz, 2H, Ar–H), 8.02 (d, J= 7.6 Hz,
2H, Ar–H), 8.76 (s, 1H, D2O exch., NH);
13C NMR
(100 MHz, DMSO-d6, d, ppm): 18.1, 114.3, 115.3, 124.6,
128.2, 128.5, 129.7, 130.1, 130.3, 131.3, 131.6, 132.3, 135.6,
141.4, 147.1, 158.5, 162.4, 170.7, 179.2; LCMS (m/z): 457
(M+); Anal. Calcd. For C25H20FN5OS: C-65.63, H-4.41, N-




Yield: 69%; m.p.: 178–180 C; IR (KBr) mmax/cm1: 3417,
3340 (NH2), 3264 (NH), 3065 (C–H, aromatic), 2927, 3008
(C–H), 1689 (C‚O), 1577 (C‚N), 1517 (C‚C), 1483, 1355
(NO2), 1325 (C‚S);
1H NMR (300 MHz, DMSO-d6, d,
ppm): 2.39 (s, 3H, CH3), 6.52 (brs, 2H, D2O exch., NH2),
7.48 (d, J= 8.2 Hz, 2H, Ar–H), 7.54 (t, J= 8.6 Hz, 2H, Ar–
H), 7.68 (t, J= 8.2 Hz, 1H, Ar–H), 7.74 (t, J= 7.4 Hz, 1H,
Ar–H), 7.83 (t, J= 8.4 Hz, 1H, Ar–H), 7.89 (d, J= 7.4 Hz,
1H, Ar–H), 7.95 (s, 1H, CH‚C), 7.99 (d, J= 8.4 Hz, 2H,
Ar–H), 8.04 (d, J= 7.6 Hz, 2H, Ar–H), 8.23 (d, J= 8.0 Hz,
1H, Ar–H), 8.76 (s, 1H, D2O exch., NH);
13C NMR
(100 MHz, DMSO-d6, d, ppm): 18.4, 110.7, 123.4, 124.1,
127.2, 128.1, 128.4, 128.7, 128.8, 129.2, 130.4, 131.3, 132.1,
134.4, 135.5, 141.3, 147.2, 147.4, 158.6, 170.8, 179.3; LCMS
(m/z): 484 (M+); Anal. Calcd. For C25H20N6O3S: C-61.97,




Yield: 66%; m.p.: 218–220 C; IR (KBr) mmax/cm1: 3423, 3338
(NH2), 3272 (NH), 3058 (C–H, aromatic), 2932, 3014 (C–H),
1691 (C‚O), 1581 (C‚N), 1510 (C‚C), 1487, 1352 (NO2),
1330 (C‚S); 1H NMR (300 MHz, DMSO-d6, d, ppm): 2.36
(s, 3H, CH3), 6.49 (brs, 2H, D2O exch., NH2), 7.44 (d,
S592 N.C. Desai et al.J= 7.2 Hz, 2H, Ar–H), 7.50 (s, 1H, CH‚C), 7.59 (t,
J= 8.6 Hz, 2H, Ar–H), 7.63 (t, J= 8.0 Hz, 1H, Ar–H), 7.99
(d, J= 8.4 Hz, 2H, Ar–H), 8.08 (d, J= 7.2 Hz, 2H, Ar–H),
8.10 (d, J= 8.4 Hz, 2H, Ar–H), 8.24 (d, J= 8.6 Hz, 2H,
Ar–H), 8.79 (s, 1H, D2O exch., NH);
13C NMR (100 MHz,
DMSO-d6, d, ppm): 18.6, 114.2, 123.8, 124.4, 128.5, 128.7,
129.2, 129.5, 130.7, 131.4, 132.2, 135.5, 141.3, 141.8, 147.2,
147.5, 158.9, 170.4, 179.8; LCMS (m/z): 484 (M+); Anal.





Yield: 61%; m.p.: 187–189 C; IR (KBr) mmax/cm1: 3422 (OH),
3417, 3357 (NH2), 3259 (NH), 3064 (C–H, aromatic), 2928,
3010 (C–H), 1683 (C‚O), 1576 (C‚N), 1515 (C‚C), 1334
(C‚S); 1H NMR (300 MHz, DMSO-d6, d, ppm): 2.31 (s, 3H,
CH3), 6.42 (brs, 2H, D2O exch., NH2), 6.70 (d, J= 8.0 Hz,
1H, Ar–H), 6.94 (t, J= 8.2 Hz, 1H, Ar–H), 7.12 (t,
J= 7.6 Hz, 1H, Ar–H), 7.49 (d, J= 7.4 Hz, 2H, Ar–H), 7.56
(t, J= 8.2 Hz, 2H, Ar–H), 7.61 (t, J= 8.4 Hz, 1H, Ar–H),
7.64 (d, J= 9.2 Hz, 1H, Ar–H), 7.71 (s, 1H, CH‚C), 7.97 (t,
J= 8.2 Hz, 2H, Ar–H), 8.03 (t, J= 7.4 Hz, 2H, Ar–H), 8.72
(s, 1H, D2O exch., NH), 9.12 (s, 1H, D2O exch., OH);
13C
NMR (100 MHz, DMSO-d6, d, ppm): 18.1, 110.5, 116.4,
117.1, 121.4, 124.6, 128.3, 128.5, 128.8, 129.2, 129.7, 130.3,
131.7, 132.1, 135.4, 141.7, 147.2, 157.3, 158.4, 170.3, 179.4;
LCMS (m/z): 455 (M+); Anal. Calcd. For C25H21N5O2S:




Yield: 64%; m.p.: 167–169 C; IR (KBr) mmax/cm1: 3428
(OH), 3416, 3364 (NH2), 3252 (NH), 3072 (C–H, aromatic),
2922, 3007 (C–H), 1687 (C‚O), 1583 (C‚N), 1520 (C‚C),
1339 (C‚S); 1H NMR (300 MHz, DMSO-d6, d, ppm): 2.88
(s, 3H, CH3), 3.93 (s, 2H, CH2), 6.69 (s, 1H, Ar–H), 6.82 (d,
J= 9.2 Hz, 1H, Ar–H), 7.14 (d, J= 8.4 Hz, 1H, Ar–H),
7.38 (s, 1H, CH‚C), 7.46 (d, J= 8.2 Hz, 2H, Ar–H), 7.52
(t, J= 8.2 Hz, 2H, Ar–H), 7.67 (t, J= 8.4 Hz, 1H, Ar–H),
7.58 (t, J= 8.6 Hz, 1H, Ar–H), 7.95 (t, J= 8.2 Hz, 2H, Ar–
H), 8.03 (t, J= 7.4 Hz, 2H, Ar–H), 8.55 (s, 1H, D2O exch.,
NH), 9.11 (s, 1H, D2O exch., OH);
13C NMR (100 MHz,
DMSO-d6, d, ppm): 18.5, 112.2, 114.4, 115.7, 121.7, 124.6,
128.1, 128.5, 129.5, 130.2, 130.6, 131.5, 132.4, 135.5, 139.8,
141.7, 147.2, 158.6, 158.9, 170.2, 179.7; LCMS (m/z): 455
(M+); Anal. Calcd. For C25H21N5O2S: C-65.92, H-4.65, N-




Yield: 66%; m.p.: 198–200 C; IR (KBr) mmax/cm1: 3421
(OH), 3413, 3356 (NH2), 3263 (NH), 3083 (C–H, aromatic),
2929, 3013 (C–H), 1684 (C‚O), 1580 (C‚N), 1517 (C‚C),
1333 (C‚S); 1H NMR (300 MHz, DMSO-d6, d, ppm): 2.33
(s, 3H, CH3), 6.42 (brs, 2H, D2O exch., NH2), 6.63 (d,
J= 7.2 Hz, 2H, Ar–H), 7.34 (s, 1H, CH‚C), 7.42 (d,
J= 8.4 Hz, 2H, Ar–H), 7.56 (t, J= 8.6 Hz, 2H, Ar–H), 7.59
(d, J= 8.2 Hz, 2H, Ar–H), 7.65 (t, J= 8.6 Hz, 1H, Ar–H),7.91 (d, J= 8.2 Hz, 2H, Ar–H), 8.04 (d, J= 7.2 Hz, 2H,
Ar–H), 8.75 (s, 1H, D2O exch., NH), 9.15 (s, 1H, D2O exch.,
OH); 13C NMR (100 MHz, DMSO-d6, d, ppm): 18.5, 114.7,
115.4, 124.2, 127.4, 128.3, 128.8, 129.5, 130.3, 131.2, 131.6,
132.9, 135.1, 141.5, 147.2, 157.4, 158.6, 170.2, 179.7; LCMS
(m/z): 455 (M+); Anal. Calcd. For C25H21N5O2S: C-65.92,




Yield: 61%; m.p.: 187–189 C; IR (KBr) mmax/cm1: 3418, 3354
(NH2), 3261 (NH), 3075 (C–H, aromatic), 2924, 3003 (C–H),
1688 (C‚O), 1575 (C‚N), 1512 (C‚C), 1337 (C‚S); 1H
NMR (300 MHz, DMSO-d6, d, ppm): 2.27 (s, 3H, CH3),
2.45 (s, 3H, CH3), 6.40 (brs, 2H, D2O exch., NH2), 7.01 (d,
J= 9.0 Hz, 1H, Ar–H), 7.21 (t, J= 8.6 Hz, 1H, Ar–H), 7.29
(t, J= 7.6 Hz, 1H, Ar–H), 7.38 (d, J= 8.4 Hz, 1H, Ar–H),
7.44 (d, J= 8.2 Hz, 2H, Ar–H), 7.53 (t, J= 8.0 Hz, 2H, Ar–
H), 7.64 (t, J= 8.6 Hz, 1H, Ar–H), 7.73 (s, 1H, CH‚C),
7.95 (t, J= 8.2 Hz, 2H, Ar–H), 8.01 (t, J= 7.6 Hz, 2H, Ar–
H), 8.69 (s, 1H, D2O exch., NH);
13C NMR (100 MHz,
DMSO-d6, d, ppm): 18.5, 19.1, 110.2, 124.5, 125.4, 127.4,
127.8, 128.2, 128.4, 128.8, 129.1, 130.4, 131.5, 132.3, 135.7,
136.1, 136.6, 141.4, 147.2, 158.5, 170.4, 179.1; LCMS (m/z):
453 (M+); Anal. Calcd. For C26H23N5OS: C-68.85, H-5.11,




Yield: 67%; m.p.: 203–205 C; IR (KBr) mmax/cm1: 3412, 3338
(NH2), 3248 (NH), 3066 (C–H, aromatic), 2937, 3011 (C–H),
1681 (C‚O), 1572 (C‚N), 1518 (C‚C), 1330 (C‚S); 1H
NMR (300 MHz, DMSO-d6, d, ppm): 2.32 (s, 3H, CH3),
2.38 (s, 3H, CH3), 6.41 (brs, 2H, D2O exch., NH2), 7.07 (s,
1H, Ar–H), 7.10 (d, J= 8.6 Hz, 1H, Ar–H), 7.19 (t,
J= 7.2 Hz, 1H, Ar–H), 7.35 (s, 1H, CH‚C), 7.40 (d,
J= 7.6 Hz, 2H, Ar–H), 7.46 (d, J= 8.4 Hz, 1H, Ar–H),
7.53 (t, J= 8.6 Hz, 2H, Ar–H), 7.61 (t, J= 8.2 Hz, 1H, Ar–
H), 7.93 (t, J= 8.6 Hz, 2H, Ar–H), 8.11 (t, J= 7.4 Hz, 2H,
Ar–H), 8.70 (s, 1H, D2O exch., NH);
13C NMR (100 MHz,
DMSO-d6, d, ppm): 18.6, 21.6, 114.5, 124.1, 125.6, 126.6,
128.4, 128.5, 128.7, 128.9, 129.6, 130.3, 131.2, 132.7, 135.1,
135.7, 138.3, 141.6, 147.3, 158.6, 170.2, 179.8; LCMS (m/z):
453 (M+); Anal. Calcd. For C26H23N5OS: C-68.85, H-5.11,




Yield: 62%; m.p.: 192–194 C; IR (KBr) mmax/cm1: 3410, 3345
(NH2), 3239 (NH), 3060 (C–H, aromatic), 2931, 3009 (C–H),
1687 (C‚O), 1579 (C‚N), 1525 (C‚C), 1335 (C‚S); 1H
NMR (300 MHz, DMSO-d6, d, ppm): 2.28 (s, 3H, CH3),
2.34 (s, 3H, CH3), 6.37 (brs, 2H, D2O exch., NH2), 7.16 (d,
J= 8.0 Hz, 2H, Ar–H), 7.33 (s, 1H, CH‚C), 7.47 (d,
J= 8.2 Hz, 2H, Ar–H), 7.53 (t, J= 7.8 Hz, 2H, Ar–H), 7.62
(d, J= 8.6 Hz, 2H, Ar–H), 7.69 (t, J= 8.6 Hz, 1H, Ar–H),
7.96 (d, J= 7.6 Hz, 2H, Ar–H), 8.07 (d, J= 8.4 Hz, 2H,
Ar–H), 8.79 (s, 1H, D2O exch., NH);
13C NMR (100 MHz,
DMSO-d6, d, ppm): 18.5, 21.1, 114.2, 124.6, 128.2, 128.3,
A new synthetic approach and in vitro antimicrobial evaluation of novel imidazole incorporated 4-thiazolidinone motifs S593128.7, 128.8, 129.6, 130.4, 131.6, 132.4, 132.8, 135.2, 137.7,
141.1, 147.5, 158.2, 170.1, 179.5; LCMS (m/z): 453 (M+);
Anal. Calcd. For C26H23N5OS: C-68.85, H-5.11, N-15.44;




Yield: 68%; m.p.: 168–170 C; IR (KBr) mmax/cm1: 3417, 3349
(NH2), 3238 (NH), 3058 (C–H, aromatic), 2927, 3009 (C–H),
1683 (C‚O), 1581 (C‚N), 1522 (C‚C), 1329 (C‚S); 1H
NMR (300 MHz, DMSO-d6, d, ppm): 2.36 (s, 3H, CH3),
3.74 (s, 3H, CH3), 6.45 (brs, 2H, D2O exch., NH2), 6.89 (d,
J= 7.2 Hz, 1H, Ar–H), 6.94 (t, J= 8.4 Hz, 1H, Ar–H), 7.25
(t, J= 8.2 Hz, 1H, Ar–H), 7.47 (d, J= 8.6 Hz, 2H, Ar–H),
7.51 (t, J= 8.4 Hz, 2H, Ar–H), 7.61 (t, J= 8.8 Hz, 1H, Ar–
H), 7.68 (d, J= 7.6 Hz, 1H, Ar–H), 7.72 (s, 1H, CH‚C),
7.93 (t, J= 8.0 Hz, 2H, Ar–H), 8.04 (t, J= 7.6 Hz, 2H, Ar–
H), 8.65 (s, 1H, D2O exch., NH);
13C NMR (100 MHz,
DMSO-d6, d, ppm): 18.1, 54.8, 110.3, 114.4, 114.7, 121.3,
124.2, 128.5, 128.6, 128.7, 128.9, 129.1, 130.4, 131.5, 132.3,
135.5, 141.3, 147.3, 158.3, 159.4, 170.6, 179.4; LCMS (m/z):
469 (M+); Anal. Calcd. For C26H23N5O2S: C-66.50, H-4.94,




Yield: 65%; m.p.: 184–196 C; IR (KBr) mmax/cm1: 3414, 3342
(NH2), 3239 (NH), 3061 (C–H, aromatic), 2925, 3005 (C–H),
1689 (C‚O), 1586 (C‚N), 1525 (C‚C), 1332 (C‚S); 1H
NMR (300 MHz, DMSO-d6, d, ppm): 2.28 (s, 3H, CH3),
3.75 (s, 3H, OCH3), 6.37 (brs, 2H, D2O exch., NH2), 6.92 (d,
J= 7.8 Hz, 2H, Ar–H), 7.37 (s, 1H, CH‚C), 7.43 (d,
J= 7.6 Hz, 2H, Ar–H), 7.52 (t, J= 8.6 Hz, 2H, Ar–H), 7.62
(t, J= 8.4 Hz, 1H, Ar–H), 7.68 (d, J= 8.4 Hz, 2H, Ar–H),
7.92 (d, J= 8.2 Hz, 2H, Ar–H), 8.03 (d, J= 8.6 Hz, 2H,
Ar–H), 8.74 (s, 1H, D2O exch., NH);
13C NMR (100 MHz,
DMSO-d6, d, ppm): 18.3, 54.2, 114.3, 114.6, 124.3, 127.3,
128.2, 128.7, 129.4, 130.1, 130.5, 131.4, 132.8, 135.2, 141.3,
147.3, 158.3, 159.2, 170.6, 179.4; LCMS (m/z): 469 (M+);
Anal. Calcd. For C26H23N5O2S: C-66.50, H-4.94, N-14.91;
Found: C-66.43, H-4.99, N-14.84%.
2.4. General procedure for preparation 2-((1-(4-(4-(arylidene)-
5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)phenyl)
ethylidene)hydrazono)thiazolidin-4-ones (4a-o)
A mixture of compounds 2-(1-(4-(4-(arylidene)-5-oxo-2-phe-
nyl-4,5-dihydro-1H-imidazol-1-yl)phenyl)ethylidene) hydra-
zinecarbothioamide (3a–o) (0.01 mol), ethyl bromoacetate
(0.01 mol) and sodium acetate (0.08 mol) in ethanol (40 mL)





Yield: 60%; m.p.: 188–190 C; IR (KBr) mmax/cm1: 3353
(NH), 3054 (C–H, aromatic), 2921, 2863 (C–H), 1688, 1708
(C‚O), 1584 (C‚N), 1508 (C‚C); 1H NMR (300 MHz,
DMSO-d6, d, ppm): 2.89 (s, 3H, CH3), 3.92 (s, 2H, CH2),6.94 (t, J= 8.4 Hz, 1H, Ar–H), 7.15 (t, J= 8.4 Hz, 2H, Ar–
H), 7.31 (d, J= 7.4 Hz, 2H, Ar–H), 7.46 (d, J= 7.2 Hz, 2H,
Ar–H), 7.55 (t, J= 8.1 Hz, 2H, Ar–H), 7.58 (t, J= 8.0 Hz,
1H, Ar–H), 7.83 (s, 1H, CH= C), 7.91 (d, J= 8.0 Hz, 2H,
Ar–H), 8.04 (d, J= 7.6 Hz, 2H, Ar–H), 8.51 (s, 1H, D2O
exch., NH); 13C NMR (100 MHz, DMSO-d6, d, ppm): 16.3,
39.5, 114.2, 124.3, 127.3, 127.5, 128.2, 128.3, 128.7, 128.8,
129.4, 130.1, 131.4, 135.2, 136.4, 141.2, 142.1, 158.3, 160.4,
170.3, 176.2; LCMS (m/z): 479 (M+); Anal. Calcd. For





Yield: 54%; m.p.: 174–176 C; IR (KBr) mmax/cm1: 3349
(NH), 3059 (C–H, aromatic), 2929, 2867 (C–H), 1693, 1703
(C‚O), 1587 (C‚N), 1512 (C‚C), 743 (C–Cl); 1H NMR
(300 MHz, DMSO-d6, d, ppm): 2.84 (s, 3H, CH3), 3.92 (s,
2H, CH2), 7.16 (t, J= 8.0 Hz, 1H, Ar–H), 7.23 (t,
J= 7.4 Hz, 1H, Ar–H), 7.34 (d, J= 8.4 Hz, 1H, Ar–H),
7.44 (d, J= 8.4 Hz, 1H, Ar–H), 7.49 (d, J= 7.2 Hz, 2H,
Ar–H), 7.57 (t, J= 8.0 Hz, 2H, Ar–H), 7.64 (t, J= 8.6 Hz,
1H, Ar–H), 7.97 (d, J= 7.6 Hz, 2H, Ar–H), 8.05 (d,
J= 7.4 Hz, 2H, Ar–H), 8.11 (s, 1H, CH‚C), 8.53 (s, 1H,
D2O exch., NH);
13C NMR (100 MHz, DMSO-d6, d, ppm):
16.5, 39.7, 110.3, 124.4, 127.6, 127.8, 128.2, 128.6, 128.7,
129.1, 129.3, 129.9, 130.6, 131.4, 132.8, 134.3, 135.5, 141.8,
142.3, 158.6, 160.3, 170.6, 176.5; LCMS (m/z): 513 (M+);
Anal. Calcd. For C27H20ClN5O2S: C-63.09, H-3.92, N-13.63;




Yield: 64%; m.p.: 232–234 C; IR (KBr) mmax/cm1: 3360
(NH), 3064 (C–H, aromatic), 2922, 2872 (C–H), 1687, 1710
(C‚O), 1584 (C‚N), 1506 (C‚C), 757 (C–Cl); 1H NMR
(300 MHz, DMSO-d6, d, ppm): 2.86 (s, 3H, CH3), 3.94 (s,
2H, CH2), 7.42 (d, J= 8.0 Hz, 2H, Ar–H), 7.48 (d,
J= 7.4 Hz, 2H, Ar–H), 7.53 (t, J= 8.2 Hz, 2H, Ar–H), 7.63
(t, J= 8.0 Hz, 1H, Ar–H), 7.68 (t, J= 8.4 Hz, 2H, Ar–H),
7.82 (s, 1H, CH‚C), 7.93 (d, J= 8.2 Hz, 2H, Ar–H), 8.02
(d, J= 7.4 Hz, 2H, Ar–H), 8.57 (s, 1H, D2O exch., NH);
13C NMR (100 MHz, DMSO-d6, d, ppm): 16.4, 39.6, 114.1,
124.6, 127.3, 128.5, 128.7, 128.9, 129.0, 129.2, 130.5, 131.6,
133.1, 134.7, 135.6, 141.4, 142.6, 158.3, 160.6, 170.5, 176.5;
LCMS (m/z): 513 (M+); Anal. Calcd. For C27H20ClN5O2S:




Yield: 61%; m.p.: 199–201 C; IR (KBr) mmax/cm1: 3352
(NH), 3072 (C–H, aromatic), 2932, 2865 (C–H), 1685, 1703
(C‚O), 1578 (C‚N), 1514 (C‚C), 1147 (C–F); 1H NMR
(300 MHz, DMSO-d6, d, ppm): 2.92 (s, 3H, CH3), 3.91 (s,
2H, CH2), 7.18 (t, J= 8.4 Hz, 1H, Ar–H), 7.21 (d,
J= 7.8 Hz, 1H, Ar–H), 7.37 (d, J= 8.2 Hz, 1H, Ar–H),
7.44 (d, J= 7.4 Hz, 2H, Ar–H), 7.56 (t, J= 8.6 Hz, 2H, Ar–
H), 7.62 (t, J= 9.0 Hz, 1H, Ar–H), 7.68 (d, J= 8.4 Hz, 1H,
Ar–H), 7.92 (d, J= 8.0 Hz, 2H, Ar–H), 8.04 (d, J= 7.2 Hz,
S594 N.C. Desai et al.2H, Ar–H), 8.10 (s, 1H, CH‚C), 8.52 (s, 1H, D2O exch., NH);
13C NMR (100 MHz, DMSO-d6, d, ppm): 16.5, 39.3, 110.8,
115.3, 123.1, 124.3, 124.7, 127.6, 128.3, 128.4, 128.7, 129.5,
129.6, 130.3, 131.8, 135.6, 141.4, 142.6, 158.3, 160.5, 161.2,
170.3, 176.7; LCMS (m/z): 497 (M+); Anal. Calcd. For





Yield: 56%; m.p.: 188–190 C; IR (KBr) mmax/cm1: 3349
(NH), 3068 (C–H, aromatic), 2929, 2864 (C–H), 1693, 1710
(C‚O), 1584 (C‚N), 1519 (C‚C), 1154 (C–F); 1H NMR
(300 MHz, DMSO-d6, d, ppm): 2.95 (s, 3H, CH3), 3.97 (s,
2H, CH2), 7.24 (d, J= 7.4 Hz, 2H, Ar–H), 7.41 (d,
J= 8.2 Hz, 2H, Ar–H), 7.56 (t, J= 8.6 Hz, 2H, Ar–H), 7.62
(t, J= 8.0 Hz, 1H, Ar–H), 7.78 (d, J= 7.4 Hz, 2H, Ar–H),
7.83 (s, 1H, CH‚C), 7.95 (d, J= 8.0 Hz, 2H, Ar–H), 8.05
(d, J= 7.6 Hz, 2H, Ar–H), 8.57 (s, 1H, D2O exch., NH);
13C NMR (100 MHz, DMSO-d6, d, ppm): 16.5, 39.2, 114.5,
115.5, 124.5, 127.4, 128.6, 128.9, 129.2, 130.5, 130.8, 131.4,
131.7, 135.5, 141.3, 142.6, 158.3, 160.5, 162.4, 170.4, 176.4;
LCMS (m/z): 497 (M+); Anal. Calcd. For C27H20FN5O2S:




Yield: 59%; m.p.: 213–215 C; IR (KBr) mmax/cm1: 3343
(NH), 3072 (C–H, aromatic), 2924, 2868 (C-–H), 1687, 1702
(C‚O), 1587 (C‚N), 1512 (C‚C), 1483, 1358 (NO2);
1H
NMR (300 MHz, DMSO-d6, d, ppm): 2.92 (s, 3H, CH3),
3.94 (s, 2H, CH2), 7.46 (d, J= 8.2 Hz, 2H, Ar–H), 7.56 (t,
J= 8.6 Hz, 2H, Ar–H), 7.64 (t, J= 8.2 Hz, 1H, Ar–H), 7.72
(t, J= 7.4 Hz, 1H, Ar–H), 7.82 (t, J= 8.4 Hz, 1H, Ar–H),
7.91 (d, J= 7.4 Hz, 1H, Ar–H), 7.96 (d, J= 8.4 Hz, 2H,
Ar–H), 8.23 (d, J= 8.0 Hz, 1H, Ar–H), 8.02 (d, J= 7.6 Hz,
2H, Ar–H), 8.34 (s, 1H, CH‚C), 8.64 (s, 1H, D2O exch.,
NH); 13C NMR (100 MHz, DMSO-d6, d, ppm): 16.7, 39.3,
110.9, 123.4, 124.6, 127.2, 127.6, 128.2, 128.3, 128.5, 128.8,
129.4, 130.6, 131.3, 134.4, 135.5, 141.7, 142.4, 147.4, 158.6,
160.7, 170.7, 176.6; LCMS (m/z): 524 (M+); Anal. Calcd.





Yield: 54%; m.p.: 187–189 C; IR (KBr) mmax/cm1: 3354
(NH), 3065 (C–H, aromatic), 2934, 2863 (C–H), 1684, 1708
(C‚O), 1583 (C‚N), 1517 (C‚C), 1489, 1362 (NO2);
1H
NMR (300 MHz, DMSO-d6, d, ppm): 2.97 (s, 3H, CH3),
3.94 (s, 2H, CH2), 7.45 (d, J= 7.2 Hz, 2H, Ar–H), 7.58 (t,
J= 8.6 Hz, 2H, Ar–H), 7.64 (t, J= 8.0 Hz, 1H, Ar–H), 7.92
(s, 1H, CH‚C), 7.99 (d, J= 8.4 Hz, 2H, Ar–H), 8.03 (d,
J= 7.2 Hz, 2H, Ar–H), 8.12 (d, J= 8.4 Hz, 2H, Ar–H),
8.28 (d, J= 8.6 Hz, 2H, Ar–H), 8.62 (s, 1H, D2O exch.,
NH); 13C NMR (100 MHz, DMSO-d6, d, ppm): 16.7, 39.2,
114.5, 123.8, 124.4, 127.7, 128.2, 128.8, 129.2, 129.4, 130.7,
131.4, 135.6, 141.1, 141.4, 142.5, 147.2, 158.1, 160.5, 170.3,





Yield: 64%; m.p.: 235–237 C; IR (KBr) mmax/cm1: 3417 (O–
H), 3354 (NH), 3073 (C–H, aromatic), 2926, 2867 (C–H),
1689, 1702 (C‚O), 1588 (C‚N), 1512 (C‚C); 1H NMR
(300 MHz, DMSO-d6, d, ppm): 2.90 (s, 3H, CH3), 6.42 (s,
2H, CH2), 6.71 (d, J= 8.0 Hz, 1H, Ar–H), 6.95 (t,
J= 8.2 Hz, 1H, Ar–H), 7.11 (t, J= 7.6 Hz, 1H, Ar–H), 7.47
(d, J= 7.4 Hz, 2H, Ar–H), 7.55 (t, J= 8.2 Hz, 2H, Ar–H),
7.60 (t, J= 8.4 Hz, 1H, Ar–H), 7.66 (d, J= 9.2 Hz, 1H, Ar–
H), 7.94 (t, J= 8.2 Hz, 2H, Ar–H), 8.02 (t, J= 7.4 Hz, 2H,
Ar–H), 8.11 (s, 1H, CH‚C), 8.53 (s, 1H, D2O exch., NH),
9.11 (s, 1H, D2O exch., OH);
13C NMR (100 MHz, DMSO-
d6, d, ppm): 16.2, 39.7, 110.3, 116.4, 117.3, 121.3, 124.6,
127.6, 128.1, 128.4, 128.6, 129.2, 129.6, 130.4, 131.6, 135.3,
141.6, 142.8, 157.3, 158.2, 160.7, 170.2, 176.6; LCMS (m/z):
495 (M+); Anal. Calcd. For C27H21N5O3S: C-65.44, H-4.27,
N-14.13; Found: C-65.51, H-4.33, N-14.20%.2.4.9. 2-((1-(4-(4-(3-Hydroxybenzylidene)-5-oxo-2-phenyl-
4,5-dihydro-1H-imidazol-1-yl)phenyl)ethylidene) hydrazono)-
thiazolidin-4-one (4i)
Yield: 53%; m.p.: 175–177 C; IR (KBr) mmax/cm1: 3414 (O–
H), 3358 (NH), 3065 (C–H, aromatic), 2922, 2872 (C–H),
1685, 1705 (C‚O), 1584 (C‚N), 1518 (C = C); 1H NMR
(300 MHz, DMSO-d6, d, ppm): 2.88 (s, 3H, CH3), 3.93 (s,
2H, CH2), 6.69 (s, 1H, Ar–H), 6.81 (d, J= 9.2 Hz, 1H, Ar–
H), 7.15 (d, J= 8.4 Hz, 1H, Ar–H), 7.47 (d, J= 8.2 Hz, 2H,
Ar–H), 7.52 (t, J= 8.2 Hz, 2H, Ar–H), 7.67 (t, J= 8.4 Hz,
1H, Ar–H), 7.58 (t, J= 8.6 Hz, 1H, Ar–H), 7.95 (t,
J= 8.2 Hz, 2H, Ar–H), 8.03 (t, J= 7.4 Hz, 2H, Ar–H), 7.86
(s, 1H, CH‚C), 8.52 (s, 1H, D2O exch., NH), 9.10 (s, 1H,
D2O exch., OH);
13C NMR (100 MHz, DMSO-d6, d, ppm):
16.2, 39.6, 112.4, 114.7, 115.4, 121.5, 124.7, 127.2, 128.1,
128.6, 129.2, 130.1, 130.5, 131.6, 135.1, 139.8, 141.6, 142.3,
158.6, 158.8, 160.3, 170.5, 176.4; LCMS (m/z): 495 (M+);
Anal. Calcd. For C27H21N5O3S: C-65.44, H-4.27, N-14.13;
Found: C-65.40, H-4.22, N-14.08%.2.4.10. 2-((1-(4-(4-(4-Hydroxybenzylidene)-5-oxo-2-phenyl-
4,5-dihydro-1H-imidazol-1-yl)phenyl)ethylidene) hydrazono)-
thiazolidin-4-one (4j)
Yield: 58%; m.p.: 165–167 C; IR (KBr) mmax/cm1: 3417 (O–
H), 3354 (NH), 3073 (C–H, aromatic), 2926, 2867 (C–H),
1689, 1701 (C‚O), 1588 (C‚N), 1512 (C‚C); 1H NMR
(300 MHz, DMSO-d6, d, ppm): 2.91 (s, 3H, CH3), 3.90 (s,
2H, CH2), 6.62 (d, J= 7.2 Hz, 2H, Ar–H), 7.43 (d,
J= 8.4 Hz, 2H, Ar–H), 7.55 (t, J= 8.6 Hz, 2H, Ar–H), 7.57
(d, J= 8.2 Hz, 2H, Ar–H), 7.66 (t, J= 8.6 Hz, 1H, Ar–H),
7.82 (s, 1H, CH‚C), 7.91 (d, J= 8.2 Hz, 2H, Ar–H), 8.04
(d, J= 7.2 Hz, 2H, Ar–H), 8.53 (s, 1H, D2O exch., NH),
9.15 (s, 1H, D2O exch., OH);
13C NMR (100 MHz, DMSO-
d6, d, ppm): 16.1, 39.3, 114.5, 115.5, 124.5, 127.1, 127.8,
128.5, 128.2, 129.6, 130.5, 131.2, 131.5, 135.6, 141.6, 142.3,
157.8, 158.6, 160.2, 170.7, 176.3; LCMS (m/z): 495 (M+);
Anal. Calcd. For C27H21N5O3S: C-65.44, H-4.27, N-14.13;
Found: C-65.49, H-4.32, N-14.22%.
A new synthetic approach and in vitro antimicrobial evaluation of novel imidazole incorporated 4-thiazolidinone motifs S5952.4.11. 2-((1-(4-(4-(2-Methylbenzylidene)-5-oxo-2-phenyl-4,5-
dihydro-1H-imidazol-1-yl)phenyl)ethylidene) hydrazono)-
thiazolidin-4-one (4k)
Yield: 65%; m.p.: 205–207 C; IR (KBr) mmax/cm1: 3348
(NH), 3068 (C–H, aromatic), 2927, 2874 (C–H), 1681,
1706 (C‚O), 1581 (C‚N), 1516 (C‚C); 1H NMR
(300 MHz, DMSO-d6, d, ppm): 2.45 (s, 3H, CH3), 2.94 (s,
3H, CH3), 3.91 (s, 2H, CH2), 7.00 (d, J= 9.0 Hz, 1H, Ar–
H), 7.21 (t, J= 8.6 Hz, 1H, Ar–H), 7.27 (t, J= 7.6 Hz,
1H, Ar–H), 7.38 (d, J= 8.4 Hz, 1H, Ar–H), 7.42 (d,
J= 8.2 Hz, 2H, Ar–H), 7.55 (t, J= 8.0 Hz, 2H, Ar–H),
7.64 (t, J= 8.6 Hz, 1H, Ar–H), 7.94 (t, J= 8.2 Hz, 2H,
Ar–H), 8.01 (t, J= 7.6 Hz, 2H, Ar–H), 8.10 (s, 1H,
CH‚C), 8.49 (s, 1H, D2O exch., NH);
13C NMR
(100 MHz, DMSO-d6, d, ppm): 16.1, 19.2, 39.6, 110.4,
124.6, 125.6, 127.1, 127.4, 127.8, 128.3, 128.6, 128.9, 129.2,
130.3, 131.5, 135.4, 136.3, 136.7, 141.3, 142.1, 158.6, 160.5,
170.6, 176.4; LCMS (m/z): 493 (M+); Anal. Calcd. For




Yield: 60%; m.p.: 184–186 C; IR (KBr) mmax/cm1: 3342
(NH), 3064 (C–H, aromatic), 2922, 2870 (C–H), 1687, 1711
(C‚O), 1585 (C‚N), 1512 (C‚C); 1H NMR (300 MHz,
DMSO-d6, d, ppm): 2.38 (s, 3H, CH3), 2.87 (s, 3H, CH3),
3.94 (s, 2H, CH2), 7.05 (s, 1H, Ar–H), 7.12 (d, J= 8.6 Hz,
1H, Ar–H), 7.20 (t, J= 7.2 Hz, 1H, Ar–H), 7.39 (d,
J= 7.6 Hz, 2H, Ar–H), 7.45 (d, J= 8.4 Hz, 1H, Ar–H),
7.54 (t, J= 8.6 Hz, 2H, Ar–H), 7.63 (t, J= 8.2 Hz, 1H, Ar–
H), 7.81 (s, 1H, CH‚C), 7.92 (t, J= 8.6 Hz, 2H, Ar–H),
8.13 (t, J= 7.4 Hz, 2H, Ar–H), 8.57 (s, 1H, D2O exch.,
NH); 13C NMR (100 MHz, DMSO-d6, d, ppm): 16.1, 21.7,
39.5, 114.6, 124.2, 125.6, 126.6, 127.3, 128.1, 128.3, 128.5,
128.8, 129.2, 130.5, 131.2, 135.3, 135.5, 138.4, 141.1, 142.6,
158.1, 160.6, 170.7, 176.1; LCMS (m/z): 493 (M+); Anal.
Calcd. For C28H23N5O2S: C-68.13, H-4.70, N-14.19; Found:
C-68.08, H-4.64, N-14.25%.2.4.13. 2-((1-(4-(4-(4-Methylbenzylidene)-5-oxo-2-phenyl-4,5-
dihydro-1H-imidazol-1-yl)phenyl)ethylidene) hydrazono)-
thiazolidin-4-one (4m)
Yield: 52%; m.p.: 196–198 C; IR (KBr) mmax/cm1: 3348
(NH), 3058 (C–H, aromatic), 2927, 2875 (C–H), 1683, 1706
(C‚O), 1587 (C‚N), 1518 (C‚C); 1H NMR (300 MHz,
DMSO-d6, d, ppm): 2.34 (s, 3H, CH3), 2.94 (s, 3H, CH3),
3.96 (s, 2H, CH2), 7.12 (d, J= 8.0 Hz, 2H, Ar–H), 7.46 (d,
J= 8.2 Hz, 2H, Ar–H), 7.52 (t, J= 7.8 Hz, 2H, Ar–H), 7.63
(d, J= 8.6 Hz, 2H, Ar–H), 7.69 (t, J= 8.6 Hz, 1H, Ar–H),
7.84 (s, 1H, CH‚C), 7.96 (d, J= 7.6 Hz, 2H, Ar–H), 8.05
(d, J= 8.4 Hz, 2H, Ar–H), 8.55 (s, 1H, D2O exch., NH);
13C NMR (100 MHz, DMSO-d6, d, ppm): 16.0, 21.1, 39.3,
114.4, 124.2, 127.4, 128.1, 128.3, 128.6, 128.8, 129.4, 130.7,
131.4, 132.4, 135.6, 137.7, 141.7, 142.4, 158.6, 160.1, 170.2,
176.5; LCMS (m/z): 493 (M+); Anal. Calcd. For




Yield: 56%; m.p.: 224–226 C; IR (KBr) mmax/cm1: 3354
(NH), 3067 (C–H, aromatic), 2932, 2870 (C–H), 1687, 1712
(C‚O), 1584 (C‚N), 1514 (C‚C); 1H NMR (300 MHz,
DMSO-d6, d, ppm): 2.91 (s, 3H, CH3), 3.74 (s, 3H, CH3),
3.96 (s, 2H, CH2), 6.88 (d, J= 7.2 Hz, 1H, Ar–H), 6.95 (t,
J= 8.4 Hz, 1H, Ar–H), 7.25 (t, J= 8.2 Hz, 1H, Ar–H), 7.45
(d, J= 8.6 Hz, 2H, Ar–H), 7.53 (t, J= 8.4 Hz, 2H, Ar–H),
7.60 (t, J= 8.8 Hz, 1H, Ar–H), 7.69 (d, J= 7.6 Hz, 1H, Ar–
H), 7.96 (t, J= 8.0 Hz, 2H, Ar–H), 8.04 (t, J= 7.6 Hz, 2H,
Ar–H), 8.10 (s, 1H, CH‚C), 8.57 (s, 1H, D2O exch., NH);
13C NMR (100 MHz, DMSO-d6, d, ppm): 16.5, 39.2, 54.8,
110.1, 114.4, 114.6, 121.3, 124.4, 127.2, 128.5, 128.6, 128.7,
128.9, 129.3, 130.5, 131.2, 135.5, 141.7, 142.3, 158.1, 159.4,
160.6, 170.2, 176.7; LCMS (m/z): 509 (M+); Anal. Calcd.





Yield: 52%; m.p.: 213–215 C; IR (KBr) mmax/cm1: 3364
(NH), 3063 (C–H, aromatic), 2943, 2876 (C–H), 1683, 1705
(C‚O), 1581 (C‚N), 1518 (C‚C); 1H NMR (300 MHz,
DMSO-d6, d, ppm): 2.95 (s, 3H, CH3), 3.75 (s, 3H, OCH3),
3.97 (s, 2H, CH2), 6.93 (d, J= 7.8 Hz, 2H, Ar–H), 7.44 (d,
J= 7.6 Hz, 2H, Ar–H), 7.56 (t, J= 8.6 Hz, 2H, Ar–H), 7.61
(t, J= 8.4 Hz, 1H, Ar–H), 7.69 (d, J= 8.4 Hz, 2H, Ar–H),
7.85 (s, 1H, CH‚C), 7.93 (d, J= 8.2 Hz, 2H, Ar–H), 8.05
(d, J= 8.6 Hz, 2H, Ar–H), 8.58 (s, 1H, D2O exch., NH);
13C
NMR (100 MHz, DMSO-d6, d, ppm): 16.4, 39.2, 54.2, 114.4,
114.7, 124.1, 127.4, 127.5, 128.6, 128.9, 129.2, 130.1, 130.3,
131.6, 135.6, 141.5, 142.4, 158.5, 159.8, 160.6, 170.7, 176.1;
LCMS (m/z): 509 (M+); Anal. Calcd. For C28H23N5O3S: C-
66.00, H-4.55, N-13.74; Found: C-65.95, H-4.49, N-13.68%.
3. Results and discussion
3.1. Chemistry
The synthetic pathways to obtain the intermediate and target
compounds in this study are depicted in Scheme 1. Com-
pounds 4-(arylidene)-2-phenyloxazol-5(4H)-ones (1) were pre-
pared in an excellent yield in one step by Perkin
condensation of hippuric acid, different substituted aldehydes
and acetic anhydride in the presence of anhydrous sodium ace-
tate. In the second step, intermediate (1) was reacted with p-
aminoacetophenone in pyridine and reﬂuxed for 4 h to furnish
product 1-(4-acetylphenyl)-4-(arylidene)-2-phenyl-1H-imida-
zol-5(4H)-ones (2). The key intermediates (3a–o) were synthe-
sized through condensation of equimolar amounts of
compound (2) and thiosemicarbazide in methanol and reﬂuxed
for 1 h. This Schiff base (3a) was characterized using IR and
NMR spectra. IR spectra showed strong absorption bands at
3370 and 3442 cm1 due to primary amine group. Absorption
band at 1330 cm1 over the range was due to C‚S stretching
vibration. The characteristic signals in 1H NMR of compound
(3a) displayed singlet at d= 6.43 ppm integrating two protons
S596 N.C. Desai et al.of the primary amine and proton of the secondary amine ap-
peared as a singlet at d= 8.70 ppm. 13C NMR spectra dis-
played a signal at 179.4 ppm assignable to thiocarbamoyl
carbon (C‚S). The mass spectrum of (3a) showed a molecular
ion peak at m/z = 439 (M+) corresponding to a molecular for-
mula C25H21N5OS. Moreover, the aforementioned schiff bases
(3a–o) were cyclized to (4a–o) through their reaction with ethyl
bromoacetate in hot ethanol for 1 h. Compound (4a) showed
strong absorption bands at 1688 and 1708 cm1 due to car-
bonyl group in IR spectra. Absorption band appeared at
3353 cm1 was due to stretching vibration corresponding to
secondary amine. In addition to this, 1H NMR spectra re-
vealed the appearance of singlet peak at d= 3.92 ppm inte-
grating two protons of the thiazolidine ring. The
characteristic signal of compound (3a) displayed singlet at
d= 8.51 ppm integrating proton of the secondary amine.
13C NMR conﬁrmed the proposed structure by appearance
of signal at d= 176.2 ppm due to carbonyl carbon as well as
the appearance of signal around d= 39.5 ppm assignable to
methylene group of the thiazolidine ring. Moreover, the mass
spectrum of (4a) showed a molecular ion peak at m/z= 479
(M+) corresponding to a molecular formula C27H21N5O2S.
3.2. Antimicrobial activity
Compounds 4a–o were evaluated against Gram-positive bacte-
ria (Staphylococcus aureus, Staphylococcus pyogenes), Gram-2
2 2 5
Scheme 1 Synthetic route for the prepnegative bacteria (Escherichia coli, Pseudomonas aeruginosa)
and fungi (Candida albicans, Aspergillus niger and Aspergillus
clavatus) strains. The individual minimal inhibitory concentra-
tion (MIC, lg/mL) values of test compounds against the test
microbes are listed in Table 1 along with MIC values of refer-
ence compounds ampicillin (for bacteria) and griseofulvin
(for fungi). The results revealed that the majority of the synthe-
sized compounds showed varying degrees of inhibition against
the test microorganisms. It was found that compounds 4h (2-
OH) and 4n (2-OCH3) showed excellent activity (50 lg/mL
and 25 lg/mL) against the gram-positive bacteria S. aureus
and S. pyogenes respectively. Among them compounds 4h (2-
OH) and 4n (2-OCH3) exhibited signiﬁcant activity against S.
aureus with the MIC value of 25 lg/mL comparable to that
of the reference drug. Compounds 4m (4-CH3) and 4h (2-OH)
showed excellent activity (12.5 lg/mL and 25 lg/mL) against
Gram-negative bacteria E. coli, while 4k (2-CH3) and 4m (4-
CH3) showed excellent activity (12.5 lg/mL and 25 lg/mL)
against P. aeruginosa. MIC values of antifungal activity,
showed that most compounds exhibited good inhibition against
the three fungal strains. Among them 4h (2-OH), 4j (4-OH), 4m
(4-CH3) and 4n (2-OCH3) exhibited strong inhibition (100 lg/
mL) against C. albicans. Compound 4j showed strong activity
(25 lg/mL) against A. niger. Compounds 4m and 4n exhibited
excellent activity (25 lg/mL) against A. clavatus.
On the basis of structure–activity relationship (SAR) stud-
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aration of title compounds (4a–o).
Table 1 Results of antibacterial and antifungal screening of compounds (4a–o).















4a -H 250 ± 3.21 500 ± 2.88* 250 ± 2.05* 500 ± 2.05* 1000 ± 3.60 1000 ± 1.20** 500 ± 4.50**
4b -2-Cl 250 ± 3.61* 500 ± 1.00* 500 ± 3.05 500 ± 3.46* 1000 ± 2.72* 1000 ± 4.04* 1000 ± 4.16
4c -4-Cl 100 ± 3.05** 100 ± 1.00*** 500 ± 4.04* 250 ± 3.60* 500 ± 4.04* 500 ± 3.70* 1000 ± 1.00*
4d -2-F 500 ± 1.60** 500 ± 1.60** 500 ± 3.21* 250 ± 3.21* 500 ± 4.35** 1000 ± 4.04* 500 ± 4.04
4e -4-F 500 ± 2.64** 250 ± 4.04 250 ± 2.04* 500 ± 3.21 500 ± 2.88* 250 ± 4.58* 100 ± 1.50***
4f -2-NO2 500 ± 3.60 500 ± 2.04
** 250 ± 1.05* 250 ± 4.16* 500 ± 2.18** 500 ± 4.16* 250 ± 3.46
4g -4NO2 500 ± 1.20
* 250 ± 3.60** 500 ± 1.16* 250 ± 1.92 1000 ± 4.60 100 ± 1.60** 250 ± 2.05**
4h -2-OH 25 ± 2.44* 50 ± 2.21** 50 ± 4.16* 25 ± 1.78* 100 ± 2.05** 50 ± 3.78 50 ± 3.52*
4i -3-OH 50 ± 3.78* 500 ± 3.78 250 ± 2.04** 250 ± 3.46 250 ± 1.52* 50 ± 1.60* 100 ± 3.78*
4j -4-OH 100 ± 1.78* 250 ± 1.21* 100 ± 4.16 50 ± 3.78** 100 ± 1.16*** 25 ± 1.18* 50 ± 3.60*
4k -2-CH3 50 ± 1.60
** 12.5 ± 3.78* 100 ± 2.64*** 100 ± 2.64** 250 ± 2.88* 100 ± 1.60* 100 ± 3.78
4l -3-CH3 500 ± 5.19
* 250 ± 1.04*** 500 ± 4.60* 100 ± 3.78*** 1000 ± 2.56* 100 ± 2.64* 500 ± 4.72*
4m -4-CH3 12.5 ± 4.40 25 ± 3.26 100 ± 3.78
** 50 ± 4.61* 100 ± 4.72 50 ± 4.16** 25 ± 1.86**
4n -2-OCH3 100 ± 3.60
*** 50 ± 1.16* 100 ± 4.50* 25 ± 3.60* 100 ± 4.04* 100 ± 4.16* 25 ± 4.04*
4o -4-OCH3 100 ± 1.52
* 100 ± 2.04** 250 ± 4.04 50 ± 2.05*** 500 ± 4.61** 50 ± 4.16 100 ± 1.00***
Ampicillin 100 ± 1.12 100 ± 1.12 250 ± 1.72 100 ± 2.24 – – –
Griseofulvin – – – – 500 ± 0.52 100 ± 1.0 100 ± 1.18
±SD= Standard deviation.
All values are presented as mean of six experiments (n= 6). All signiﬁcant differences are considered from control value 0.00.
* P< 0.05 signiﬁcant.
** P< 0.01 moderately signiﬁcant.

































































S598 N.C. Desai et al.imidazole derivatives was markedly inﬂuenced by the electron
donating substituents and the incorporation of electron
donating group caused enhanced activity against most test
microorganisms. Compounds 4h, 4j, 4k, 4m and 4n with
electron-donating substituents (OH, CH3 and OCH3) in the
aromatic ring were more active against all test bacteria and
fungi than compounds having electron-withdrawing groups.
Notably, compounds 4k and 4m showed highest inhibition
against bacterial strains E. coli and P. aeruginosa respectively
at MIC 12.5 lg/mL. Furthermore, compounds 4h and 4n
showed signiﬁcant inhibition against bacterial strains S. aureus
and S. pyogenes at MIC 50 and 25 lg/mL respectively. Com-
pounds 4m and 4n showed highest inhibition against fungal
strains C. albicans and A. clavatus. From the data of biological
activity, we can presume that, to get most potent antimicrobial
agents, compounds must contain electron releasing group as
substitution. Therefore the electron releasing groups induced
a positive effect and the electron withdrawing groups induced
a negative effect on the biological activity.
4. Biological evaluation
4.1. Antibacterial assay
The newly synthesized compounds (4a–o) were screened for
their antibacterial activity against Gram-positive bacteria (S.
aureus (MTCC-96), S. pyogenes (MTCC-442)) and Gram-
negative bacteria (E. coli (MTCC-443), P. aeruginosa (MTCC-
1688). All MTCC cultures were collected from the Institute
of Microbial Technology, Chandigarh. The activity of com-
pounds was determined as per the National Committee for
Clinical Laboratory Standards (NCCLS) protocol using Muel-
ler Hinton Broth (Becton Dickinson, USA) (Finegold and
Garrod, 1995; Desai et al., 2012f). Compounds were screened
for their antibacterial activity as primary screening in six sets
against E. coli, S. aureus, P. aeruginosa and S. pyogenes at dif-
ferent concentrations of 1000, 500, and 250 lg/mL. The com-
pounds found to be active in primary screening were
similarly diluted to obtain 200, 125, 100, 62.5, 50, 25 and
12.5 lg/mL concentrations for secondary screening to test in
a second set of dilution against all microorganisms. Inoculum
size for test strain was adjusted to 106 CFU/mL (Colony
Forming Unit per milliliter) by comparing the turbidity (turbi-
dimetric method). Mueller Hinton Broth was used as nutrient
medium to grow and dilute the compound suspension for test
bacteria. Two percent DMSO was used as a diluent/vehicle to
obtain the desired concentration of synthesized compounds
and standard drugs to test upon standard microbial strains.
Synthesized compounds were diluted to 1000 lg/mL concen-
tration, as a stock solution. The control tube containing no
antibiotic was immediately subcultured [before inoculation]
by spreading a loopful evenly over a quarter of the plate of
medium suitable for the growth of test organisms. The tubes
were then put for incubation at 37 C for 24 h for bacteria.
Ten micrograms per milliliter suspensions was further inocu-
lated on an appropriate media and growth was noted after
24 h and 48 h. The highest dilution (lowest concentration) pre-
venting appearance of turbidity was considered as minimum
inhibitory concentration (MIC, lg/mL) i.e. the amount of
growth from the control tube before incubation (which repre-sents the original inoculum) was compared. A set of tubes con-
taining only seeded broth and solvent controls were
maintained under identical conditions so as to make sure that
the solvent had no inﬂuence on strain growth. The result of
this is greatly affected by the size of inoculum. The test mixture
should contain 106 CFU/mL organisms. Standard drug used in
the present study was ‘ampicillin’ for evaluating antibacterial
activity which showed 100, 100, 250 and 100 lg/mL MIC
against E. coli, P. aeruginosa, S. aureus and S. pyogenes
respectively.
4.2. Antifungal assay
The same compounds (4a–o) were tested for antifungal activ-
ity as primary screening in six sets against C. albicans, A.
niger and A. clavatus at various concentrations of 1000, 500,
and 250 lg/mL. The compounds found to be active in pri-
mary screening were similarly diluted to obtain 200, 125,
100, 62.5, 50 and 25 lg/mL concentrations for secondary
screening to test in a second set of dilution against all micro-
organisms. Griseofulvin was used as a standard drug for anti-
fungal activity, which showed 500, 100 and 100 lg/mL MIC
against C. albicans, A. niger and A. clavatus respectively.
For fungal growth, in the present protocol, we have used Sab-
ourauds dextrose broth at 28 C in an aerobic condition for
48 h.
4.3. Statistical analysis
Standard deviation value was expressed in terms of ±SD. On
the basis of calculated value by using one-way ANOVA meth-
od followed by independent two sample t test, it has been ob-
served that differences below 0.001 level were considered as
statistically signiﬁcant.
5. Conclusion
The new compounds (4a–o) presented hereby signiﬁcantly dif-
fer in their corresponding antimicrobial activity depending on
the type of substituent. In the course of this study, particularly
derivatives possessing electron donating groups such as
methyl, methoxy and hydroxy were identiﬁed as exhibiting po-
tent groups for antibacterial activity against bacterial strains
and antifungal activity against fungal strains. Structure–
activity relationship studies showed that the antimicrobial
potency is mainly inﬂuenced by the substituent at 2 and
4-positions on the benzene ring of imidazole ring. It may be
considered as a promising lead for further design and develop-
ment of new chemical entities. The results described here, merit
further investigations in our laboratory using a forward
chemical genetics approach for ﬁnding lead molecules as
antimicrobial agents.Acknowledgment
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